期刊文献+

曲格列酮对大鼠垂体腺瘤GH3细胞CD147、TGF-β1和MMP-9表达的影响 被引量:1

Effects of troglitazone on the expressions of CD147, TGF-β1 and MMP-9 in GH3 cells
原文传递
导出
摘要 目的探讨过氧化物酶体增殖激活物受体γ(PPAR-γ)的配体曲格列酮(TGZ)对大鼠垂体腺瘤GH3细胞系白细胞分化抗原147(CD147)、转化生长因子β1(TGF-β1)和基质金属蛋白酶9(MMP-9)表达的影响。方法GH3细胞分为空白对照组和实验组(TGZ浓度分别为1×10-3、1×10-4和1×10-5mol/L)。TGZ作用GH3细胞48 h后,分别采用Western blot和荧光定量PCR检测各组细胞中CD147、TGF-β1、MMP-9蛋白和mRNA的表达。结果各组细胞CD147、TGF-β1、MMP-9蛋白和mRNA的表达与空白对照组相比,均有统计学差异(P均<0.05),而且TGZ浓度越高,CD147、TGF-β1、MMP-9蛋白和mRNA的表达量越低。结论 PPAR-γ配体TGZ能降低CD147、TGF-β1、MMP-9的表达,并可能通过该作用减弱GH3细胞的侵袭力。 Objective To explore the effect of troglitazone(TGZ), a ligand for peroxisome proliferator-activated receptor γ(PPAR-γ), on the expressions of cluster of differentiation 147(CD147), transforming growth factor beta 1(TGF-β1) and matrix metalloproteinase 9(MMP-9) in rat GH-secreting GH3 cells. Methods GH3 cells were devided into control group and experimental groups (1×10-3, 1×10-4 and 1×10-5 mol/L TGZ). After treated with TG2 for 48 hours, expressions of CD147, TGF-β1 and MMP-9 at protein and mRNA levels were detected by Western blot and Real-time PCR respectively. Results The expressions of CD147, TGF-β1 and MMP-9 at protein and mRNA levels in all the TGZ treated groups showed significant differecnces compared with control group(all P〈0.05). Moreover, expressions of the above three indicators decreased both at protein and mRNA levels when TGZ concentration was increased. Conclusion TGZ can inhibit expressions of CD147, TGF-β1 and MMP-9, which might relieve the invasiveness of GH3 cells.
出处 《山东大学学报(医学版)》 CAS 北大核心 2013年第3期6-9,共4页 Journal of Shandong University:Health Sciences
基金 山东省科技发展计划项目(2010GSF10225) 山东省自然科学基金(Y2008C64)
关键词 垂体腺瘤 过氧化物酶体增殖激活物受体Γ 白细胞分化抗原147 转化生长因子β1 基质金属蛋白酶9 GH3细胞 Pituitary adnoma; Peroxisome proliferators activated receptor γ; Cluster of differentiation 147; Transforming growth factor beta 1; Matrix metalloproteinase 9; GH3 cells
  • 相关文献

参考文献18

  • 1范胜强,徐广明,姜萌,刘渤,赵华,杨伟.TSP-1、TGF-β和PPAR-γ在脑胶质瘤中的表达及其与微血管密度的关系[J].山东大学学报(医学版),2012,50(2):53-56. 被引量:3
  • 2Heaney A P, Fernando M, Melmed S. PPAR-gamma re?ceptor ligands: novel therapy for pituitary adenomas[J] .J Clin Invest, 2003,111 (9) : 1381-1388.
  • 3Pasche B. Role of transforming growth factor beta in cancer[J].J Cell Physiol, 2001,186(2):153-168.
  • 4Butz H, Lik6 I, Czirjdk S, et al. MicroRNA profile indi?cates downregu1ation of the TGF[3 pathway in sporadic non-functioning pituitary adenomas[J]. Pituitary, 2011, 14(2) :112-124.
  • 5Dallago C M, Barbosa-Coutinho L M, Ferreira N P, et al. Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adeno?masJ J]. Endocr Patho1, 2010, 21(1) :32-39.
  • 6Recouvreux M V, Guida M C, Rifkin DB, et al. Active and total transforming growth factor-Bl are differentially regulated by dopamine and estradiol in the pituitary[J] . Endocrinology, 2011, 152(7) :2722-2730.
  • 7杨伟,曲元明,徐广明,韩韬.TSP1/TGFβ与垂体瘤血管生成及侵袭性的关系[J].中华神经外科杂志,2005,21(11):695-698. 被引量:6
  • 8Renner U, Lohrer P, Schaaf L, et al. Transforming growth factor-B stimulates vascular endothelial growth fac?tor production by folliculostellate pituitary cells[J]. En?docrinology, 2002, 143 (10) :3759- 3765.
  • 9Ruebel K H, Leontovich A A, Tanizaki Y, et al. Effects of TGFbetal on gene expression in the HP75 human pitui?tary tumor cell line identified by gene expression profiling [J]. Endocrine, 2008, 33 (1) :62-76.
  • 10Renno T, Wilson A, Dunkel C, et al. A role for CD147 in thymic development[J].J Immun, 2002, 168 ( 10) : 49464950.

二级参考文献15

  • 1杨伟,曲元明,徐广明,韩韬,牟成志.在垂体腺瘤中TSP-1和TGF-β1的表达及其与微血管密度的关系[J].中华内分泌代谢杂志,2007,23(1):44-46. 被引量:6
  • 2NorJ E, Mitra RS, Sutorik MM, et al. Thrombospondin 1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J VascRes, 2000, 37:209 - 218.
  • 3Rennet U, Lohrer P, Schaaf L, et al. Transforming growth factor-βstimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology, 2002, 143:3759 - 3765.
  • 4Jugenburg M, Kovacs K, Stefaneanu L, et al. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic study. Endocr Pathol, 1995, 6:115 - 124.
  • 5Vidal S, Kovacs K, Horvath E, et al. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch, 2001, 438:595 - 602.
  • 6Turner HE, Nagy Z, Gatter KC, et al. Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome. J Endocrinol, 2000, 165:475 - 481.
  • 7Itoh J, Serizawa A, Kawai K, et al. Vascular networks and endothelial cells in the rat experimental pituitary glands and in the human pituitary adenomas. Microscopy Research and Technique,2003, 60:231 - 235.
  • 8Fraipont F, Nicholson AC, Feige J J, et al. Thrombospondins and tumor angiogenesis. Trends Mol Med, 2001, 7:401 - 407.
  • 9Weidner N, Intrantumor microvessel density as progenostic factor in cancer. Am J Pathol,1995, 147:9 - 13.
  • 10Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenis witch during tumorigenesis. Cell, 1996,86:353 - 364.

共引文献25

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部